Amiphenazole, a respiratory stimulant, can be used parenteral and oral. Nicholas Laboratories marketed it under the trade name Daptazole. It was used to treat chronic respiratory failure, by increasing ventilation and by reduction of the pCO2 in some patients. Increased ventilation was brought about by an increase in tidal volume rather than an increase in respiratory rate. In combination with bemegride, amiphenazole was used as an antidote for barbiturate, glutethimide overdose, as well as poisoning from other sedative drugs. Now, this drug is used very rarely, because it replaced by more effective drugs.